INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$109.35
+4.62 (+4.41%)
Financial Highlights (FY 2026)
Revenue
1.26M
Net Income
-135,931,939
Gross Margin
—
Profit Margin
-10,773.5%
Rev Growth
-16.0%
D/E Ratio
12.58
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 56.7% | 56.7% |
| Operating Margin | -10,386.5% | -9,347.9% | -23.7% | -26.0% |
| Profit Margin | -10,773.5% | -10,234.8% | -30.0% | -23.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.26M | 1.50M | 384.43M | 347.35M |
| Gross Profit | — | — | 217.96M | 196.94M |
| Operating Income | -130,985,279 | -140,307,963 | -91,253,184 | -90,196,370 |
| Net Income | -135,931,939 | -145,606,694 | -115,444,062 | -82,575,244 |
| Gross Margin | — | — | 56.7% | 56.7% |
| Operating Margin | -10,386.5% | -9,347.9% | -23.7% | -26.0% |
| Profit Margin | -10,773.5% | -10,234.8% | -30.0% | -23.8% |
| Rev Growth | -16.0% | -16.0% | -5.8% | +11.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 745.44M | 745.44M | 85.85M | 85.10M |
| Total Equity | 59.25M | 59.25M | 832.96M | 791.72M |
| D/E Ratio | 12.58 | 12.58 | 0.10 | 0.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -128,640,369 | -145,451,500 | -155,644,267 | -144,289,075 |
| Free Cash Flow | — | — | -85,235,104 | -84,943,791 |